NuCana plc reported second quarter 2026 financial results, posting a net loss of £3.1 million compared to £24.1 million in the prior year period. For the six months ended June 30, 2026, the company recorded a net loss of £6.9 million against £26.6 million previously. Cash and cash equivalents stood at £19.5 million as of June 30, 2026, with management stating these resources are sufficient to fund operations into 2029. The company completed patient recruitment in its Phase 2 NuTide:701 expansion study evaluating NUC-7738 in combination with pembrolizumab for PD-1 inhibitor-resistant metastatic melanoma and anticipates presenting final data later in 2026. NuCana operates as a clinical-stage biopharmaceutical company developing ProTide technology-based medicines to treat cancer.